OSI Systems
OSIS
$197.49
-3.31%
OSI Systems Inc is a designer and manufacturer of electronic systems and components for the homeland security, healthcare, defense, and aerospace markets, operating through three segments: Security, Healthcare, and Optoelectronics & Manufacturing. The company is a niche player with a strong position in security screening and inspection systems, deriving the majority of its revenue from the United States. The current investor narrative centers on the stock's recent sharp sell-off following a sales miss, despite management's accelerated 2027 guidance and robust free cash flow, leading to debate about whether the market's reaction is overdone.…
OSIS
OSI Systems
$197.49
Related headlines
Investment Opinion: Should I buy OSIS Today?
We rate OSIS a Buy, anchored by a Strong Buy consensus (1.43) and an average analyst target of $298.14, implying 44.2% upside. The thesis is that the market has overreacted to a single sales miss, ignoring the company's accelerating revenue growth (10.5% YoY), robust free cash flow ($142.3M), and a forward PE of 15.8x that prices in a recovery. With a trailing PE of 24.4x and a PS of 2.12x, the stock trades at a discount to its growth potential, offering a favorable risk/reward for patient investors.
Sign up to view all
OSIS 12-Month Price Forecast
The AI model leans bullish, driven by the compelling valuation gap (forward PE 15.8x) and strong analyst conviction, despite the recent sales miss. The market's negative reaction appears overdone given the company's cash generation and growth trajectory. However, confidence is medium due to the high PEG ratio and leverage, which could amplify downside if growth disappoints. The stance would upgrade to high confidence if OSIS delivers a strong Q3 beat and raises guidance, while a downgrade would occur if revenue growth decelerates below 5% or the company cuts its 2027 outlook.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on OSI Systems's 12-month outlook, with a consensus price target around $278.29 and implied upside of +40.9% versus the current price.
Average Target
$278.29
0 analysts
Implied Upside
+40.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$250 - $300
Analyst target range
Analyst coverage is moderate, with 7 analysts providing ratings, and the consensus is a 'Strong Buy' with a mean recommendation score of 1.43 (where 1 is Strong Buy and 5 is Sell). The average price target is $298.14, implying a significant upside of 44.2% from the current price of $206.73. The target range spans from $270.00 to $320.00, with the low target still representing a 30.6% upside, indicating that even the most bearish analyst sees substantial value. The high target of $320.00 suggests a potential 54.8% upside, reflecting confidence in the company's growth prospects. Recent ratings actions have been predominantly positive, with firms like Roth Capital and B. Riley maintaining Buy ratings, while JP Morgan holds a Neutral stance, indicating a generally bullish sentiment but with some caution.
Bulls vs Bears: OSIS Investment Factors
OSIS presents a classic value-versus-momentum dilemma. The bull case rests on strong analyst conviction (44% upside), accelerating revenue, robust free cash flow, and a forward PE of 15.8x that implies substantial earnings growth. The bear case is driven by the recent sales miss, a sky-high PEG of 54.4x, high leverage, and persistent underperformance versus the market. Currently, the bearish sentiment dominates the price action, but the fundamental data suggests the sell-off may be overdone. The key tension is whether the sales miss is a temporary blip or a sign of structural demand weakness—if the former, the stock is deeply undervalued; if the latter, the forward PE could be misleading. Evidence slightly favors the bulls given the strong analyst targets and cash flow, but the market's negative momentum warrants caution.
Bullish
- Strong Buy consensus with 44% upside: Analysts rate OSIS a Strong Buy (mean 1.43) with an average target of $298.14, implying 44.2% upside from the current $206.73. Even the lowest target of $270 offers 30.6% upside, reflecting broad confidence in the company's recovery.
- Accelerating revenue growth: Q2 FY2026 revenue grew 10.5% YoY to $464.1M, accelerating from Q1's $384.6M. This sequential improvement suggests demand is strengthening despite the recent sales miss, supporting management's accelerated 2027 guidance.
- Robust free cash flow generation: TTM free cash flow stands at $142.3M, providing ample liquidity for debt reduction, investments, or buybacks. This cash generation underpins the company's ability to navigate near-term volatility and fund growth initiatives.
- Attractive forward valuation: The forward PE of 15.8x is well below the trailing PE of 24.4x, implying the market expects ~54% EPS growth. This discount suggests the stock is priced for a recovery, offering value if the company meets its 2027 targets.
Bearish
- Recent sales miss triggers sell-off: The latest quarter missed sales expectations, causing a sharp 5.2% drop on August 21, 2026, and a 29.4% decline over six months. This miss raises doubts about demand sustainability and near-term growth visibility.
- Extremely high PEG ratio: The PEG ratio of 54.4x is extraordinarily elevated, indicating the stock is expensive relative to its expected earnings growth. This suggests the market is pricing in aggressive growth that may not materialize, leaving room for disappointment.
- High debt-to-equity ratio: Debt-to-equity stands at 1.20x, indicating significant leverage. While manageable, this increases financial risk, especially if interest rates remain elevated or cash flows weaken, potentially constraining flexibility.
- Underperformance vs. market: OSIS is down 5.1% over the past year and 29.4% over six months, while the S&P 500 gained 20.5% over the same period. This persistent underperformance reflects negative sentiment and a lack of investor confidence.
OSIS Technical Analysis
OSIS is in a pronounced downtrend, with the stock down 5.1% over the past year and 29.4% over the past six months, significantly underperforming the S&P 500, which gained 20.5% over the same period. The current price of $206.73 sits at 66.3% of its 52-week range (between $186.50 and $311.72), indicating the stock is closer to its lows than its highs, reflecting persistent selling pressure and a bearish sentiment. The 52-week low of $186.50 is a critical support level, while the high of $311.72 represents a formidable resistance zone.
Beta
1.20
1.20x market volatility
Max Drawdown
-36.2%
Largest decline past year
52-Week Range
$187-$312
Price range past year
Annual Return
-14.0%
Cumulative gain past year
| Period | OSIS Return | S&P 500 |
|---|---|---|
| 1m | -15.1% | -1.4% |
| 3m | -14.5% | +3.3% |
| 6m | -27.1% | +15.1% |
| 1y | -14.0% | +17.2% |
| ytd | -22.7% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OSIS Fundamental Analysis
Revenue growth has been solid, with the most recent quarter (Q2 FY2026, ended December 31, 2025) showing revenue of $464.1 million, up 10.5% year-over-year, and a sequential acceleration from Q1's $384.6 million. The company's product segment generated $350.8 million in revenue, while services contributed $113.3 million, indicating a diversified revenue stream. However, the recent sales miss in the latest quarter has raised concerns about demand sustainability, though the accelerated 2027 guidance suggests management expects a rebound.
Quarterly Revenue
$464057000.0B
2025-12
Revenue YoY Growth
+10.5%
YoY Comparison
Gross Margin
32.7%
Latest Quarter
Free Cash Flow
$142327000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OSIS Overvalued?
Given that OSIS has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 24.4x, while the forward PE is 15.8x, implying the market expects significant earnings growth (approximately 54% increase) over the next year. This forward discount is substantial and suggests that the market is pricing in a strong recovery, which may be optimistic given the recent sales miss. The PEG ratio of 54.4x is extremely high, indicating that the stock is expensive relative to its expected earnings growth rate, though this metric can be distorted by cyclical earnings.
PE
24.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 9x~39x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are notable: OSIS carries a debt-to-equity ratio of 1.20x, indicating significant leverage that could strain cash flows if interest rates rise or earnings falter. The company's net margin of 8.7% is modest, and the recent sales miss suggests revenue concentration in security products may be vulnerable to order timing. However, free cash flow of $142.3M provides a cushion, and the current ratio of 3.15x indicates ample short-term liquidity. The high PEG ratio of 54.4x implies that any shortfall in growth expectations could lead to multiple compression, amplifying downside risk.
FAQ
The key risks are: 1) Financial risk from high leverage (D/E 1.2x) and modest net margin (8.7%), which could strain if earnings decline. 2) Competitive risk in security screening, where larger players could pressure market share. 3) Macro risk, as the stock's beta of 1.21 means it is more volatile than the market, and rising interest rates could compress multiples. 4) Company-specific risk of further sales misses, which would likely trigger analyst downgrades and a slide toward the 52-week low of $186.50. The most severe risk is a combination of these factors leading to a -35% downside from current levels.
The 12-month forecast is bullish, with a base case target of $298.14 (45% probability), a bull case of $320 (30% probability), and a bear case of $186.50 (25% probability). The most likely scenario is a gradual recovery to the average analyst target, driven by the company's growth trajectory and undervaluation. The key assumption is that the recent sales miss is temporary and that management's 2027 guidance is achievable. If OSIS delivers strong Q3 results, the stock could move toward the bull case; if it disappoints, the bear case becomes more likely.
OSIS is undervalued on a forward basis, with a forward PE of 15.8x versus the trailing 24.4x, implying the market expects significant earnings growth. The PS ratio of 2.12x and EV/EBITDA of 20.2x are reasonable for a growth company. However, the PEG ratio of 54.4x is extremely high, suggesting that if growth fails to materialize, the stock could be overvalued. The market is pricing in a strong recovery, and if that occurs, the stock is cheap; if not, it could be expensive. Relative to its own history and peers, the current valuation is at a discount, offering a margin of safety.
OSIS appears to be a good buy for investors with a 12-month horizon, given the 44% upside to the average analyst target of $298.14 and the forward PE of 15.8x, which is attractive relative to the trailing 24.4x. The recent sales miss has created a buying opportunity, but the high PEG ratio of 54.4x and leverage (D/E 1.2x) warrant caution. If you believe the sales miss is temporary and the company can achieve its 2027 targets, the risk/reward is favorable. However, for risk-averse investors, waiting for confirmation of a turnaround in the next earnings report may be prudent.
OSIS is better suited for long-term investment (3-5 years) given its growth potential and current undervaluation. The stock's beta of 1.21 and recent volatility make it less suitable for short-term trading, as price swings can be significant. The company's strong free cash flow and market position in security and healthcare provide a foundation for sustained growth. However, investors should be prepared for near-term volatility and hold through earnings cycles to capture the full upside. A minimum holding period of 12 months is recommended to allow the thesis to play out.